Published in Cancer Weekly, January 8th, 2008
"We proposed to address these concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses. Subjects with stage II (>= 6 + LN), III, or stage IV breast cancerwith > 50% HER2 overexpressing tumor cells who were disease-free after...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.